[quick news] on May 25, 2018, Suzhou University and others joined hands to help the domestic research and development of all maglev artificial heart

Suzhou University and others have jointly assisted in the research and development of full magnetic levitation artificial heart in China It is reported that the full magnetic levitation artificial heart developed by Suzhou Tongxin Medical Equipment Co., Ltd in cooperation with Suzhou University, Beijing Fuwai Hospital and other units has achieved satisfactory results in its first clinical application This technology not only realizes the great development of the application of artificial heart to treat patients with heart failure, but also is expected to open a new era of surgical treatment of heart failure in China Http://news.scienceet.cn/htmlnews/2018/5/412883.shtm national key R & D plan 7 key special overall expert groups were established In order to implement the key special management tasks of the national key R & D plan, give full play to the role of experts in the special process management, and ensure the smooth implementation of the special tasks, the high technology research and development center of the Ministry of science and technology recently held the general expert group establishment meeting of seven key special projects such as "nanotechnology" in Beijing Experts of the general expert group, relevant departments and bureaus of the Ministry of science and technology, high technology center and relevant special management personnel attended the establishment meeting, which was chaired by Bian Shuguang, deputy director of the high technology center Http:// the first new drug for the treatment of thrombocytopenia has been approved by the U.S FDA recently, the U.S FDA approved the new drug doplet (avatrompag) tablet of akarx, a subsidiary of dova pharmaceuticals, for the treatment of adult patients with chronic liver disease (CLD) who plan to undergo medical or dental surgery It is reported that this is the first drug approved for this use Https:// Roche's first-line lung cancer therapy announced the latest results Recently, gene tech, a subsidiary of Roche Group, announced the positive results of 3-phase clinical trial, impower 150 This study evaluated the efficacy and safety of tecentriq (atezolizumab) combination therapy in the first-line treatment of patients with metastatic non squamous non-small cell lung cancer (NSCLC) who had not received chemotherapy Https:// EU approved the use of Aspen product cabometyx in the treatment of advanced renal cell carcinoma According to recent reports from pharmaceuticals, the European Commission has approved the use of Ipsen / exelixi drug cabometyx in the first-line treatment of adult advanced renal cell carcinoma (RCC) Data from the cabosun trial showed that cabometyx (cabozantinib) prolonged progression free survival (PFS) in patients with advanced RCC at intermediate or low risk who were initially treated http://